Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Average Rating of "Buy" from Analysts

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) has been given a consensus recommendation of "Buy" by the five ratings firms that are presently covering the company, Marketbeat.com reports. Five analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued a report on the stock in the last year is $33.00.

Several equities analysts recently weighed in on the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $50.00 target price on shares of Aardvark Therapeutics in a research report on Tuesday, April 1st. Morgan Stanley assumed coverage on shares of Aardvark Therapeutics in a research report on Monday, March 10th. They set an "overweight" rating and a $29.00 target price on the stock. Bank of America raised their price target on Aardvark Therapeutics from $22.00 to $26.00 and gave the stock a "buy" rating in a research report on Thursday, March 27th. Wall Street Zen lowered Aardvark Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. Finally, Royal Bank Of Canada reduced their price target on shares of Aardvark Therapeutics from $21.00 to $20.00 and set an "outperform" rating on the stock in a research note on Thursday, May 15th.

Hedge Funds Weigh In On Aardvark Therapeutics

Several institutional investors have recently bought and sold shares of AARD. Walleye Capital LLC purchased a new stake in Aardvark Therapeutics during the first quarter valued at approximately $88,000. Goldman Sachs Group Inc. purchased a new stake in shares of Aardvark Therapeutics in the 1st quarter valued at $153,000. Adage Capital Partners GP L.L.C. acquired a new stake in Aardvark Therapeutics during the 1st quarter worth about $1,878,000. Braidwell LP acquired a new stake in Aardvark Therapeutics during the first quarter worth about $3,755,000. Finally, Cormorant Asset Management LP purchased a new position in shares of Aardvark Therapeutics during the 1st quarter valued at approximately $6,009,000.

Aardvark Therapeutics Stock Up 3.0%

Aardvark Therapeutics stock traded up $0.40 during trading hours on Monday, reaching $13.92. The stock had a trading volume of 10,562 shares, compared to its average volume of 81,073. Aardvark Therapeutics has a 52 week low of $4.88 and a 52 week high of $19.58. The company's fifty day simple moving average is $11.27.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.01).

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.